2020
Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function
Foster GG, Grant MJ, Thomas SM, Cameron B, Raiff D, Corbet K, Loitsch G, Ferreri C, Horwitz M. Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function. Transplantation And Cellular Therapy 2020, 26: 1597-1606. PMID: 32450288, PMCID: PMC8026759, DOI: 10.1016/j.bbmt.2020.05.007.Peer-Reviewed Original ResearchConceptsAllogeneic hematopoietic cell transplantHematopoietic cell transplantChronic kidney diseaseRenal functionFoscarnet treatmentCell transplantHuman herpes virus-6 (HHV-6) reactivationLong-term renal functionAcute kidney injuryAcute kidney failureTransplant-related factorsAllo-HCTFoscarnet useMedian eGFRsKidney injuryAdult patientsFrequent indicationKidney diseaseKidney failureFoscarnetAnti-infective agentsMultivariate analysisPatientsOptimal managementMonths
2018
Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function
Foster Y, Grant M, Thomas S, Cameron B, Raiff D, Corbet K, Ferreri C, Horwitz M. Treatment with Foscarnet after Allogeneic Hematopoietic-Cell Transplant (AlloHCT) Is Associated with Long-Term Loss of Renal Function. Blood 2018, 132: 4594. DOI: 10.1182/blood-2018-99-113189.Peer-Reviewed Original ResearchLong-term renal functionAcute kidney failureAcute kidney injuryChronic kidney diseaseRenal functionChronic GVHDNephrotoxic drugsHuman herpes virus-6 (HHV-6) reactivationAllogeneic hematopoietic cell transplantEnd-stage renal diseaseAlternative donor graftsHHV-6 viremiaUnadjusted median survivalRetrospective cohort studyHematopoietic cell transplantTransplant-related factorsGlomerular filtration rateSerum creatinine valuesMultivariate logistic regressionCKD-EPI equationUmbilical cord bloodManual chart reviewAcute GVHDEGFR declineLower eGFRs